Fig. 3
Box plots of the baseline, 6 h, 12 h, and 24 h urine [TIMP-2]*[IGFBP7] values. Log-transformed data area shown. The boxes and whiskers correspond to interquartile ranges and total ranges, respectively. Each dot represents an individual value. Urine [TIMP-2]*[IGFBP7] was significantly higher in patients with persistent AKI than in those with transient AKI. At baseline (n = 184), median [IQR] value of 2.21 [0.81–4.90] vs. 0.75 [0.20–2.12] (ng/ml)2/1000 (p < 0.001); at 6 h (n = 172), median [IQR] value of 2.02 [0.54–5.43] vs. 0.37 [0.13–1.38] (ng/ml)2/1000 (p < 0.001); at 12 h (n = 165), median [IQR] value of 1.19 [0.30–3.8] vs. 0.33 [0.13–0.78] (ng/ml)2/1000 (p < 0.001); and at 24 h (n = 156), median [IQR] value of 0.69 [0.26–2.36] vs. 0.32 [0.12–0.86] (ng/ml)2/1000 (< 0.001). TIMP-2, tissue inhibitor of metalloproteinases-2; IGFBP-7, insulin-like growth factor-binding protein 7; AKI, acute kidney injury; IQR, interquartile range